Clinical outcomes among patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who received treatment with a covalent BTK and BCL2 inhibitor in the United States : a real-world database study
This retrospective study using the nationwide de-identified Flatiron Health electronic health record-derived database was designed to evaluate clinical outcomes among patients with chronic lymphocytic leukemia (CLL) who previously received both a covalent Bruton's tyrosine kinase inhibitor (cBTKi) and B-cell lymphoma 2 inhibitor (BCL2i) in a real-world setting. Outcomes for the immediate next line of therapy following the latter of the cBTKi or BCL2i treatment included: real-world response rate of 34.4% (using methods most consistent with clinical trials); median duration of real-world response of 13.3 months; and median real-world progression-free survival of 9.2 months. Median overall survival was 25.5 months from the start of the immediate next line of therapy. There remains a need for more effective therapies after cBTKi and BCL2i therapy for patients with CLL.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:64 |
|---|---|
| Enthalten in: |
Leukemia & lymphoma - 64(2023), 5 vom: 29. Mai, Seite 1005-1016 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Eyre, Toby A [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 08.06.2023 Date Revised 09.06.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/10428194.2023.2190436 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM354926071 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM354926071 | ||
| 003 | DE-627 | ||
| 005 | 20231226063254.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/10428194.2023.2190436 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1183.xml |
| 035 | |a (DE-627)NLM354926071 | ||
| 035 | |a (NLM)36987650 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Eyre, Toby A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical outcomes among patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who received treatment with a covalent BTK and BCL2 inhibitor in the United States |b a real-world database study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.06.2023 | ||
| 500 | |a Date Revised 09.06.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a This retrospective study using the nationwide de-identified Flatiron Health electronic health record-derived database was designed to evaluate clinical outcomes among patients with chronic lymphocytic leukemia (CLL) who previously received both a covalent Bruton's tyrosine kinase inhibitor (cBTKi) and B-cell lymphoma 2 inhibitor (BCL2i) in a real-world setting. Outcomes for the immediate next line of therapy following the latter of the cBTKi or BCL2i treatment included: real-world response rate of 34.4% (using methods most consistent with clinical trials); median duration of real-world response of 13.3 months; and median real-world progression-free survival of 9.2 months. Median overall survival was 25.5 months from the start of the immediate next line of therapy. There remains a need for more effective therapies after cBTKi and BCL2i therapy for patients with CLL | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Chronic Lymphocytic Leukemia | |
| 650 | 4 | |a Covalent BTK inhibitor | |
| 650 | 4 | |a Real-World Data | |
| 650 | 4 | |a venetoclax | |
| 650 | 7 | |a Agammaglobulinaemia Tyrosine Kinase |2 NLM | |
| 650 | 7 | |a EC 2.7.10.2 |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Proto-Oncogene Proteins c-bcl-2 |2 NLM | |
| 650 | 7 | |a BCL2 protein, human |2 NLM | |
| 700 | 1 | |a Hess, Lisa M |e verfasserin |4 aut | |
| 700 | 1 | |a Sugihara, Tomoko |e verfasserin |4 aut | |
| 700 | 1 | |a He, Dan |e verfasserin |4 aut | |
| 700 | 1 | |a Khanal, Manoj |e verfasserin |4 aut | |
| 700 | 1 | |a Pagel, John M |e verfasserin |4 aut | |
| 700 | 1 | |a Walgren, Richard A |e verfasserin |4 aut | |
| 700 | 1 | |a B Abada, Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Konig, Heiko |e verfasserin |4 aut | |
| 700 | 1 | |a Roeker, Lindsey E |e verfasserin |4 aut | |
| 700 | 1 | |a Mato, Anthony |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Leukemia & lymphoma |d 1989 |g 64(2023), 5 vom: 29. Mai, Seite 1005-1016 |w (DE-627)NLM012624047 |x 1029-2403 |7 nnns |
| 773 | 1 | 8 | |g volume:64 |g year:2023 |g number:5 |g day:29 |g month:05 |g pages:1005-1016 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/10428194.2023.2190436 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 64 |j 2023 |e 5 |b 29 |c 05 |h 1005-1016 | ||